These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. Falorni A; Gambelunghe G; Forini F; Kassi G; Cosentino A; Candeloro P; Bolli GB; Brunetti P; Calcinaro F J Clin Endocrinol Metab; 2000 Jan; 85(1):309-16. PubMed ID: 10634404 [TBL] [Abstract][Full Text] [Related]
7. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes. Ujihara N; Daw K; Gianani R; Boel E; Yu L; Powers AC Diabetes; 1994 Aug; 43(8):968-75. PubMed ID: 8039604 [TBL] [Abstract][Full Text] [Related]
8. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Padoa CJ; Banga JP; Madec AM; Ziegler M; Schlosser M; Ortqvist E; Kockum I; Palmer J; Rolandsson O; Binder KA; Foote J; Luo D; Hampe CS Diabetes; 2003 Nov; 52(11):2689-95. PubMed ID: 14578287 [TBL] [Abstract][Full Text] [Related]
9. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Reijonen H; Daniels TL; Lernmark A; Nepom GT Diabetes; 2000 Oct; 49(10):1621-6. PubMed ID: 11016444 [TBL] [Abstract][Full Text] [Related]
10. The first 142 amino acids of glutamate decarboxylase do not contribute to epitopes recognized by autoantibodies associated with Type 1 diabetes. Wyatt RC; Brigatti C; Liberati D; Grace SL; Gillard BT; Long AE; Marzinotto I; Shoemark DK; Chandler KA; Achenbach P; Gillespie KM; Piemonti L; Lampasona V; Williams AJK Diabet Med; 2018 Jul; 35(7):954-963. PubMed ID: 29577424 [TBL] [Abstract][Full Text] [Related]
11. Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. Kobayashi T; Tanaka S; Okubo M; Nakanishi K; Murase T; Lernmark A J Clin Endocrinol Metab; 2003 Oct; 88(10):4768-75. PubMed ID: 14557453 [TBL] [Abstract][Full Text] [Related]
12. Association of amino-terminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus. Hampe CS; Nalini R; Maldonado MR; Hall TR; Garza G; Iyer D; Balasubramanyam A J Clin Endocrinol Metab; 2007 Feb; 92(2):462-7. PubMed ID: 17090641 [TBL] [Abstract][Full Text] [Related]
13. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes. Daw K; Powers AC Diabetes; 1995 Feb; 44(2):216-20. PubMed ID: 7532143 [TBL] [Abstract][Full Text] [Related]
14. Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus. Hampe CS; Radtke JR; Wester A; Carlsson A; Cedervall E; Jönsson B; Ivarsson SA; Elding Larsson H; Larsson K; Lindberg B; Neiderud J; Rolandsson O; Lernmark Å Diabet Med; 2019 Nov; 36(11):1375-1383. PubMed ID: 30264481 [TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes. Lühder F; Schlosser M; Mauch L; Haubruck H; Rjasanowski I; Michaelis D; Kohnert KD; Ziegler M Autoimmunity; 1994; 19(2):71-80. PubMed ID: 7772705 [TBL] [Abstract][Full Text] [Related]
16. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome. Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930 [TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Powers AC; Bavik K; Tremble J; Daw K; Scherbaum WA; Banga JP Clin Exp Immunol; 1999 Dec; 118(3):349-56. PubMed ID: 10594551 [TBL] [Abstract][Full Text] [Related]
18. Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition. Primo ME; Anton EA; Villanueva AL; Poskus E; Ermácora MR Clin Immunol; 2003 Jul; 108(1):38-45. PubMed ID: 12865069 [TBL] [Abstract][Full Text] [Related]
19. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351 [TBL] [Abstract][Full Text] [Related]
20. The PEVKEK region of the pyridoxal phosphate binding domain of GAD65 expresses a dominant B cell epitope for type 1 diabetes sera. Tong JC; Myers MA; Mackay IR; Zimmet PZ; Rowley MJ Ann N Y Acad Sci; 2002 Apr; 958():182-9. PubMed ID: 12021103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]